Kathleen I. Pritchard, MD
Until recently, it has not been considered standard practice to administer adjuvant systemic therapy after surgery to any group of women with node-negative breast cancer (1). These women have relatively few relapses, only 25% to 28% at 10 years, compared with a 10-year relapse rate of 75% in women with node-positive disease (2, 3). Overall survival rates, similarly, are 65% to 82% at 10 years for women with node-negative disease and 25% to 40% for women with involved axillary nodes (2, 3). Recurrence and survival rates for node-negative women are, however, still far from ideal.
Before 1988, only a few
Pritchard KI. Systemic Adjuvant Therapy for Node-Negative Breast Cancer: Proven or Premature?. Ann Intern Med. ;111:1–4. doi: 10.7326/0003-4819-111-1-1
Download citation file:
Published: Ann Intern Med. 1989;111(1):1-4.
Breast Cancer, Hematology/Oncology.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use